REVIEW ARTICLE

Promising Drug Delivery System for Cervical Cancer – A Future Approach

Gayatri S Ahir, Rahul G Ingle*

Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (DMIHER), Deemed to be University, Wardha, Maharashtra, India.

Received: 27th July, 2024; Revised: 10th August, 2024; Accepted: 19th August, 2024; Available Online: 25th September, 2024

ABSTRACT

There is evidence that peptide targeting can be applied in cervical cancer therapy and for diagnosis involving the use of molecular imaging, hence developing peptide probes for this disease. Cervical cancer, which also has a high possibility of being prevented, is among the common tumors affecting women globally. Despite the occurrence being reduced greatly by screening, the illness remains fatal and its claims many lives annually, especially in the developing nations. In exercising such a perspective, specific public health efforts known to encourage physical activity, proper diet, and early detection of cervical cancer must begin to be taken seriously. When combined, doctors, health officers, and lawmakers could speed up the global deployment of such programs. California's American Cancer Society, the present review enlists a host of pharmaceutical goods available in the market. This perspective of present-day research and manufacturing is devoted to the development of various types of nanocarriers for possible utilization in medication transport. Thus, overall cancer mortality appears to be not substantially different, though cancer incidence rates for both sexes are 50% lower in impoverished countries when compared to affluent nations. At the moment, there are new peptide probes that are developed solely for cervical cancer-perfectly suitable for targeting peptides applicable in therapeutic and diagnostic imaging. M13KE phage dodecapeptide (12-mer) peptide library was screened for recognition of human immunodeficiency virus type 1 (HIV-1) by immunofluorescence and flow cytometry; the S7 clone was identified as most suitable. A disease that affects many women is gynecologic health problems, and cervical cancer is the leading presenting complaint experienced regularly. Among these studies, QSAR, drug-likeness, PCA, dynamic cross-correlation matrix, molecular docking, molecular dynamics and quantum calculation properties can be listed. In the first literature survey, after identifying the potent antibacterial and anticancer activity of the molecule apigenin, some other promising derivatives were identified and more research has been carried out on them, focusing on their synthesized derivatives as inhibitors of DNA polymerase theta and cervical cancer caused by human papillomavirus. The results were streamlined by the use of *in-silico* molecular docking, which showed that all Apigenin derivatives and the targeted proteins had potential energy-binding relationships. Further validation is essential because this study used *in-silico* computational methodologies and produced excellent results. Applying *in-silico* molecular docking made the data more comprehensible, which showed the possible energy bindings of the targeted proteins and all the Apigenin variants. Due to the fact that this work utilized *in-silico* computational methods and obtained significant results, further validation is required. Hence, the present wet-lab experiments coupled with both *in-vitro* and *in-vivo* conditions, additional validation of the results.

Keywords: Cervical cancer, Antisense lncRNA, Magnetic thermosensitive cationic liposome, Oxaliplatin.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.75

How to cite this article: Ahir GS, Ingle RG. Promising Drug Delivery System for Cervical Cancer – A Future Approach. International Journal of Drug Delivery Technology. 2024;14(3):1785-1790.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

As it is revealed, cervical cancer, or uterine cervix carcinoma, is the second most common type of cancer and its rate is comparatively high and the mortality rate is also comparatively high. HIV/Acid-infected countries often rarely get to access these common chemotherapy procedures and surgeries. The direction of development of cancer-related research today is to provide better therapy for cervical cancer. Such therapies include gene therapy, recombinant-protein, photodynamic therapy, photothermal therapy, and chemotherapeutic agents delivered through hydrogels, liposomes and nanoparticles. Another target of approaches to probe local drug/medicine delivery to the by sick place and prevent large effects on the body are localized delivery systems that include intravaginal

**Author for Correspondence: rahul.pharmacy@dmiher.edu.in*

rings, intravaginal patches and intravaginal films. The following assessment involves several systems and distribution methods that are currently present in organizations. Thus, cervical cancer is the second most threatening type of cancer for women globally, along with the most lethal one in the developing states.[1-3] Unfortunately, to date, there is no cure for this disease.[1] Thus, due to the need for better drug efficacy, a drug targeting cervical cancer has to be improved. Cervical cancer is primarily an identification of an infection with the human papillomavirus (HPV). The oncoproteins E6 and E7 of HPV can activate the Hh signaling pathway to control the movement, liveliness and multiplication of cervical cancer cells. Since possible candidates for modulators of the Shh signaling pathway, a new class of herbaric acid derivatives was developed and synthesized in the present research. Cervical cancer has been discussed in relation to the International Federation of Gynaecology and Obstetrics (FIGO) which has set standards for clinical staging of the cancer. Treatment-wise, however, there are three subtypes of cervical cancer.[2] Those that fall into stage IA1, microinvasive diseases which are rarely treated with surgery as a first-line treatment and IIA1 for tumors of less than 4cm in size in the upper part of the vagina. Supercim is a new trend that the pharmaceutical industry has applied to fasten the medication development process through the utilization of CADD methods. Efficiency in decreasing costs, time and number of failures has been the major drive, especially in the last steps of it. Among all the diseases, colorectal cancer (CC) remains one of the most outstanding and widespread diseases for women.[3] It can be caused by people mobilizing against vaccines or persuading others not to take vaccines, the absence of screening programs, or the poor funding and access to treatment. The implementation and distribution of effective and widely popular HPV vaccinations, together with other improvements in the healthcare sector, are two ways that can be used to reduce cervical cancer in developed nations. However, the immunizations are only prophylactic, which means that they are helpful only in the case of healthy clients and have no curative role within the context of an infection that is already present. To provide a more detailed view of contemporary patterns in cervical cancer incidence and related mortality as well as HPV prevalence, we outline current cervical cancer demographic incidence and death rates along with HPV data within the context of the IARC's 2008 global cancer incidence database. Two types of HPV vaccines can also protect against the human papillomavirus types 16 and 18, which are behind 40 to 60% cancer of the cervix precursors and 70 to 75% of cervical cancer. About 135 women diagnosed with cervical cancer stages IB–IIA underwent pelvic lymph node dissections and radical abdominal hysterectomy. Intratumoral cytosol samples were analyzed by enzyme immunoassay for the levels of VEGF. A test for activating the mTOR pathway was done on a tissue microarray of cervical cancer. Pharmacic assays were performed to determine how the dosages of rapamycin or, siRNA silencing after mTOR inhibition impacted the viability of HeLa cells and downstream signaling.[4] In developing countries, cervical cancer still remains the leading killer of women of reproductive age and the second leading cause of cancer-related mortality in women globally. Therefore, on analyzing the inhibition of mTOR followed by studying the trend for the viability of HeLa cells and the subsequent signaling pathways are the effects of raising the dosages of rapamycin or siRNA silencing pursued.

Cervical cancer is still the leading cause of death among women of childbearing age in such low-income or barring any progression such countries and ranks second to cancer death among women in the world. It is produced in large quantities and used in almost all physiological processes ranging from immunity and inflammation. However, one can only wonder about ways in which NO is involved in the biology of tumors or cancers. The inducible NOS (iNOS/NOS-2) isoform maintains the levels of NO. It has a biphasic effect on cancer in numerous forms bearing both pro as well as anti-tumorigenic properties associated with the optimized level of NO at a molecular level. Available options for cytotoxic therapeutic interventions are fairly fewer in the situation of progressive cervical carcinoma. The response rates were within 20 to 30% and the overall survival (OS) with the most used cytotoxic treatment, combination chemotherapy (CC) was not more than 10 months. This comes due to the low efficiency of cytotoxic therapy as one of the methods of cervical cancer treatment that has raised the need for personalized drugs. Treatment of HPV disease is not available at the moment but the intensity of the sign can be regulated. It is possible for many business revenues to be shed, some types of IC could result in damages, and there can be several human capital losses to the scientific community. New studies proposed that deficiency in HR is synthetically lethal and that DNA polymerase theta is the next target for the treatment of the lack of HR tumors. It consists of three parts and it occupies a few 8,000 bp at the most. This is a small double-stranded DNA molecule, which is intercalary and is evolutionarily conserved very much. That is why the molecular biochemistry of this little DNA molecule is rather obscure and hardly deciphered. Phylogenetically conserved sequences of 4,000 bp reside in seven genes that are affiliated with transcription/replication cellular change. Among them seven are early proteins, three oncoproteins which are E5, E6 and E7 while three are regulatory proteins which include E1, E2 and E4.[5]

The genomic information of L1 and L2 accounts for the viral capsid and they are located in two separate segments of 3,000 bp of DNA. The long control region (LCR) is a 1000 bp that contains the transcriptional regulation and the viral DNA replication. The pathogenicity of the virus depends on L1 protein to enhance the attachment of the virion to the heparin sulfate receptors in the basal membrane30. The E1 protein reassembles into a hexameric complex once again. This recruits topoisomerase I, replication protein A (RPA), and DNA polymerase all of which are involved in replication. Cancer-related fatalities from the study it can be seen that in certain false –negative Pap smears there is usually only a few abnormally shaped cells on the slide. This is not ref citing style as per journal guidelines. Pls correct. The two major issues that have been provided for this problem are improper transfer of cells from collecting devices to the slide or improper sampling. The development of biomarkers is mainly targeted at the refinement of cancer recognition and defining a particular individual's predisposition to cancer. First-line chemoradiation therapy belongs to second-line therapy for locally advanced patients (IB2–IVA). Uncertainty regarding the best practice in adjuvant systemic chemotherapy and neoadjuvant chemoradiation has led to their assessment as potential treatments for this patient group in randomized phase III trials. Systemic chemotherapy should be the treatment of tendency for patients with relapsed or persistent illness that does not react to curative treatment, as well as the majority of advanced cases, including IVB stages. The eighth reference source – A recent Phase III trial concludes that supplementation of bevacizumab results in the enhancement of PFS and overall survival. As opposed to pregenomic medicines or conventional chemotherapy, postgenomic drugs or target drugs were known to focus on the genetic abnormality of the tumor; the therapy's viability for clinical testing would depend on it. At the same time, it is necessary to note that there is no designated medication used to cure cervical cancer directly.

Compared to the knowledge on other cancers, information regarding targeted molecular changes in cervical carcinoma is severely deficient. Besides, locally advanced and cervical cancer are undesired types of tumors. Furthermore, the market dictates the present approach to cancer medication development. Up to this date, the only way to obtain any information on the frequency of mutations in cervical cancer that may be targeted was from the Sanger database. An extensive one on the genetic landscape of cervical cancer was released to the public. In the study, sequencing was performed on 115 cervical carcinoma-normal matched whole exome sequencing samples, 14 pairs of tumor and normal samples and 79 transcriptome sequencing cases. Not surprisingly, among the samples, the frequency of PIK3CA mutation was 14%, whereas that of PTEN and STK11 was 6 and 4%, respectively. Besides other undiscovered somatic mutations, the scientists pinpointed the E322K substitution within the MAPK1 gene in 8% of cases and the inactivating HLA-B gene mutation in 9% of patients with breast cancer; EP300 in 16%; FBXW7 in 15%; NFE2L2 in 4%; TP53 in 5% and ERBB2 in 6%. In addition, it was possible to identify somatic mutations in CBFB in 8% of the samples and in ELF3 in 13% of the analyzed cases, where the examined tumor was an adenocarcinoma. Notably, out of six identified ERBB2 variants, three variants, namely S310F, S310Y, and V842I are recognized as being driver mutation in oncogenic processes.[6]

For the early stages (IB1 and IIA less than 4 cm), there are two therapeutic options: or radiation therapy or radical hysterectomy with removal of the lymph nodes.[5] There are two main categories of radiation that is administered on the pelvis: external beam and internal radiation or what is commonly referred to as brachytherapy. Female patients who are surgery candidates and present risk indicators during pathologic evaluation may receive radiation therapy alongside or instead of chemotherapy to eliminate the chances of relapse. Radiation with cisplatin-based chemotherapy, adjuvant radiation after surgery, or surgery along with cisplatin chemotherapy are the available treatments for the wider localized tumors (IB2 and IIA bigger than 4 cm).

Currently there is not enough data to tell whether one approach of follow-up following treatment may be better or worse than another in terms of how long people live after, on quality of life and management. And it is common knowledge that radiation degrades over time as well. Cervical cancer ranks fourth in female cancer mortality and incidence. Cervical screening is a common diagnostic tool, and in case of further suspicion, biopsy is carried out. Hence, wet-lab research *in-vitro* and to a lesser extent *in-vivo* would be necessary to further confirm the results. In this work, the activity of DNA polymerase is studied by *in-silico* exploration on various Apigenin derivatives.

Biomarkers for Cervical Cancer

Stem cell biomarkers have been archived and therapeutic targets are also being established in the possible "strategies that enhance the therapeutic ratio in personalized medicine." This paper gives a brief insight into the probable utility of cervical CSC biomarkers in diagnosing, prognosticating as well as in the therapeutic course. The Pap smear has been the mainstay of cervical screening for almost 50 years, and its use has led to a reduction in the cervical cancer mortality rate.[7] From the outcomes, when there are a few fragmented and dysplastic cells appearing on the slide, the cytological pattern in some false-negative Pap smears comes out as benign. The two most common causes for this issue that have been posted so far are failure on the part of the collecting devices to transfer adequate cells to the slide or insufficient sampling. Two categories of clinical biomarkers exist: Some of the uses are: (1) predictive indices let one predict the toxicity, survival, duration without relapse, sensitivity to treatment, and clinical effectiveness of the intended treatment; (2) diagnostic markers help in diagnosis; and (3) some of them can serve both purposes. P prognostic signs are significant for the evaluation of the illness and its course and are associated with angiogenesis, invasion, metastasis, proliferation, and differentiation of carcinoma. Biomarkers, therefore, can facilitate early clinical management decisions in particular whether it is better to treat the patients, discharge, have frequent follow-up, or refer to colposcopy. Biomarkers also help in tracking the efficiency of the treatment, the probable side effects of the treatment, and the prognosis of the patient. Since some drugs for particular patients or patient categories may be developed and prescribed based on the unique biomarkers for the highest level of patient benefit, biomarkers are necessary for precision medicine. There is, however improvement in the use of biomarkers for recognition of cervical CSCs in the last 10 years. That ordeal was conducive to putting together several findings regarding stem cell biomarkers in general and their identification and characterization specifically due to diagnostic purposes, certain biomarkers have been identified, such as viral (HPV16), stem cell and transcription factors and CSC surface markers (ALDH1, CD44). Until now, works have focused in assessing the stemness of CSCs and have identified different gene expressions in cervical CSCs. Such kinds of studies offer the potential for increasing the precision of diagnosis, the prognosis of the individual's reaction to the treatment and overall health.[7]

MATERIALS AND METHODS

We reviewed the records of all patients (1991–2000) with invasive cervical cancer regarding medical history, disease-related risk factors, pathological findings and treatment schedule/tumor response/overall survival.

The vast majority of patients reported not being able to come back for their next treatments following their initial careynchronously. Most three-quarters indicated that they could not afford it. We were in fact, supposed to try and make phone calls or establish mail relationships whenever we could. It is summed up to have refined the method of acquiring information. External beam radiation therapy (EBRT) was given to the entire pelvis by 2 or 4 field box technique with a liner accelerator-Cobalt Therapy Unit of 10 MV. Gamma Med III system PlasmaVis In this version of the GammaMed, brachytherapy used 3 Cs-137 sources.

To do this, it involves the use of a written prescription that shows how mitomycin, cisplatin and 5-fluorouracil were combined for CCRT.

Probabilities ratios and Spearman's correlation test were conducted using SPSS version 9.08.

The efficiency of pembrolizumab in patients with advanced cervical cancer who showed PD-L1 expression (TPS ≥1%) was similar to its activity in other tumor types. This disease is caused by sexual intercourse with the human papillomavirus virus, which is an icosahedral, non-enveloped, double-stranded DNA virus. The first is skin infection, followed by squamous epithelia lining the upper respiratory or anogenital tracts as well as any other organs' mucous membranes. More than one hundred different HPV species are known; approximately forty types among them infect the perianal area. There are about eighteen recognized carcinogenic strains of HPVs and some common ones are HPV-16 HPV-18. Low-risk/non-oncogenic HPVs like HPV-6 and HPV-11 cause genital warts. It takes around one to two years after infection for cell-mediated immunity to develop most time.

Diagnosis and Secondary Prevention

Cervical cancer and precursors to cervical cancer can be found through screening tests. Most medical institutions recommend that screening of the cervix, including early signs of precancer, should begin at 21 years old. These tests are often repeated over several years. The U.S.A., like other developed countries, has employed Pap smears for more than 50 years to detect dysplasia and early cancerous signs in the cytology of the cervix. The frequency of invasive squamous cell carcinoma of the cervix has dropped significantly due to screening. Another histologic subgroup that develops in the mucous-secreting epithelium is Adenocarcinoma. The doctor will scrape some cells off your cervix during a Pap test." After, these cells are taken to a laboratory where they will be tested for any changes in their behavior.

Pap testing is used to diagnose cervical cancer by detecting malignant cells on or within the uterus. It also indicates variations within cells which enhance susceptibility toward malignancy in the cervix. Cervical cell samples for an HPV DNA test are examined for the presence of variable strains associated with an increased likelihood of cervical cancer.

They are referred to as precancerous cells[7]. HPV DNA testing is a test to detect the infection of cervical cells with any of the HPV strains that are most likely to cause cervical cancer. If there is reason to believe that you might have cervical cancer, the next thing that is done is a very detailed examination of your cervix. Cancerous growths are looked for using a colposcope, which is a specialized magnifying instrument.

During the colposcopic examination, a physician takes a cervical cell sample for laboratory analysis. The sample may be obtained by:

Punch biopsy: In this, several small tissue samples are taken from the cervix by pricking it with a sharp instrument.

Endocervical curettage is the procedure in which a sample of tissue from the cervix is obtained with a fine brush or small spoon-shaped instrument (curette). Vaginal cancer may be in one of four stages. If the number is 1, cancer is limited to the cervix. The higher the numbers, the more advanced the cancer is.

Current Medication Used to Treat Cervical Cancer

Almost all uterine cervical cancer cases are supposed to have an infection with oncogenic HPV strains through the cervix epithelium. More than 30 types of HPV are associated with oncogenic potential; more than seventy others have been identified to be non-oncogenic. 4, 5 The oncogenic types are: HPV-16 (in decreasing order of frequency), followed by 18, 45,31,33.58.52..35..59...56...6....68......39.......82.........73........66 go general

Cervical cytology is the primary of detecting cervical malignancy early. The test during pregnancy will put mothers and their unborn children at no risk. Other studies have suggested that the accuracy of cervical cytological diagnosis is similar in pregnant and nonpregnant women.

As is the current standard of care for cervical cancer, she noted that chemotherapy remains the first-line recommendation in cases not limited to very early disease, which might benefit from surgery to help achieve a curative outcome.[8,9]

Standard therapy for locally advanced stages is still based on radiation and cisplatin-based chemotherapy. In addition to platinum drugs, some other recently developed agents can enhance the effects of radiation, chemotherapy and hormone therapy. Those medications usually depend on molecular targeting. In some contexts, other cell cycle-targeting therapies, such as vincristine. Gemcitabine, paclitaxel, and 5-fluorouracil can potentially augment or radio-sensitize the lethal effects of cisplatin. The advanced-stage disease is too advanced to be treated by systemic pharmaceutical intervention.

The course of treatment for cervical cancer depends on several factors, such as your preferences, the stage of the cancer, and any comorbidity. Surgery, radiation therapy, chemotherapy, or a combination of the three may be used.

- Surgery to remove the malignancy
- Trachelectomy: surgery to remove the cervix
- Hysterectomy: surgery to remove uterus
- Radiation therapy
- Chemotherapy
- Targeted therapy

Vaccines for Cervical Cancer

HPV vaccines are one of the best ways to prevent cervical cancer. Good news: More vaccine congress to save people using the herd immunity approach before exposure (i.e., prevent cervical cancer cases and increasing mortality). But the WHO findings, reported earlier this week in India, heralded a new dawn with targeted Benefits of the cervical cancer vaccine. Cervavac vaccine commercialization is indeed an intervening breakthrough for public health as it horned good life-saving prevention. A recent breakthrough innovation by the World Health Organization (WHO) has demonstrated that novel vaccines can theoretically Cure adult patients who had severe human papillomavirus (HPV) infection long before progressing through most Indian Health Systems would have undoubtedly converted into malignant tumorous growths causing Metastatic-Cervix Cancers and then Treatments of Malignancy.[10]

These include Cervarix, Gardasil and the newer version of Gardasil 9. Who developed Cervavac (under development; to be launched in 2021): This is currently under Development by the Serum Institute of India. The sustainable development goals (SDGs) will be this year's plan of action and they have put an end to costing lives with what UN chief Ban Ki-moon called "a new global commitment that aims at ending all forms of malnutrition". If one applies the same logic to the epidemiology of cervical cancer, then in places like 17TEST where women have limited access to accurate high-resolution tests for HPV with implementation of timely treatment using site-specific 'screen and treat' are organized along comprehensive management guidelines. HPV DNA screening for (High Penetration) (prophylactic HPV vaccination)-in general population/screening age women HRP-(b). Key strategies for more effectively communicating the value of getting vaccinated against HPV include spreading such information and fighting misinformation. Researchers said numerous studies have demonstrated that vaccination results in a reduced incidence of HPV infection, precancerous lesions and cervical cancer 9 to 14-year-olds should receive two doses 6 months apart, and 15 to 26-year-olds should receive three doses: 0, 1-2 and 6 months. The cover page lists the targeted populations, as well as the safety and efficacy required of candidates, medical reasons for which the vaccine should be given, and operational considerations (dosing intervals, storage and route of administration, cost).

There are even now more than 20 therapeutic HPV vaccine candidates in various stages of development and some are even undergoing clinical trials.[11,12]

Efficacy and Safety of Cervavac

Cervavac's efficacy and safety have been assessed in a large number of investigations and clinical trials.[13] Preventing HPV infection, precancerous lesions, and cervical cancer has been shown to be highly effective using cervical cancer vaccination. According to clinical research, Cervavac offers strong resistance against HPV strains 16 and 18, which account for over 70% of instances of cervical cancer. To further lower the risk of cervical cancer, the vaccination also provides cross-protection against a number of additional high-risk HPV strains.

Additionally, Cervavac has passed thorough safety assessments. Like other cervical cancer vaccinations, slight soreness, redness, or swelling at the injection site are common adverse effects of this one as well. The dangers of vaccination are greatly outweighed by the benefits, which seldom include serious adverse responses. For maximum safety and efficacy, it is crucial to stick to the advised immunization schedule and seek medical advice.

Colorectal (288 000 deaths), and breast (458 000 deaths). 86% of cervical cancer cases and 88% of cervical cancer-related fatalities happened in poor nations. The ASIR and ASMR were 18 and 10 per 100,000 developed countries. 1.9% of women in developing countries had a cervical cancer diagnosis, and 1.1% of those women died from the disease.

CONCLUSION

The majority of the time, HPV infection of the cervical epithelium is associated with uterine cervical cancer, and primary prophylaxis against oncogenic HPV strains is best achieved with vaccination. The most effective secondary prophylaxis for individuals who are outside the recommended vaccination age range and who have already contracted carcinogenic strains of HPV is liquid-based cervical cytologic screening in conjunction with HPV reflex testing atypical squamous cells of unclear significance. More than a quarter of a million women die from cervical cancer each year; these deaths mostly affect young women in developing countries. It continues to be a major public health issue. Both high-income and low- and middle-income countries may be able to reduce the morbidity and death from cancer thanks to recently developed, efficient preventative measures. It should possess surveillance, comprising excellent cancer registries linked to screening and vaccination registries. Track the outcomes of these precautionary steps and provide the foundation for lobbying, international action, and national policy. In conclusion, although cervical cancer still poses a threat to women's health, it may be the first disease that humans may completely eliminate via the implementation of suitable preventive and control methods.

Improved knowledge of the mutational landscape and the development of novel targeted medicines may result in cervical cancer treatments that are more individualized and effective. Recalling the potential therapeutic advantage of removing the E6 and E7 HPV oncoproteins—the two primary alterations linked to cervical cancer—is crucial. Nonetheless, there has been some progress in characterizing the mutational landscape of cervical cancer, indicating that a limited number of these targetable mutations are presently compatible with already available medications.

ACKNOWLEDGMENT

The authors are thankful to the Datta Meghe Institute of Higher Education and Research, Wardha, for their financial support.

REFERENCES

1. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The Lancet. 2019; 393(10167):169-182. https://doi.org/10.1016/S0140-6736(18)32470-X
2. Akash S, Bayıl I, Hossain MS, Islam MR, Hosen ME, Mekonnen AB, Nafidi HA, Bin Jardan YA, Bourhia M, Bin Emran T. Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives. Scientific Reports. 2023; 13(1):16565. https://doi.org/10.1038/s41598-023-43175-x
3. Krakauer EL, Kwete X, Kane K, Afshan G, Bazzett-Matabele L, Bien-Aimé DD, Byrne-Martelli S, Connor S, Correa R, Devi CB, Diop M. Cervical cancer-associated suffering: estimating the palliative care needs of a highly vulnerable population. JCO Global Oncology. 2021; 7:862-872. https://doi.org/10.1200/GO.21.00025
4. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational oncology. 2021; 14(10):101174. https://doi.org/10.1016/j.tranon.2021.101174
5. Wu X, Qiu L, Lou W, Wang X, Zhu T, Zhang Y, Hu W, Xue X, Zhu Z, Xiang L, Li J. A multicenter non-inferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stages IB1, IB2, and IIA1): study protocol of the LAUNCH 2 trial. Trials. 2022; 23(1):269. https://doi.org/10.1186/s13063-022-06245-5
6. Moleyar-Narayana P, Leslie S, Ranganathan S. Cancer screening. StatPearls. 2024.
7. Cho CJ, Brown JW, Mills JC. Origins of cancer: ain't it just mature cells misbehaving? The EMBO Journal. 2024:1-22. https://doi.org/10.1038/s44318-024-00099-0
8. Obaid AL-Mawla1 BS, Khalil MA, Murshid RM, Ameen BA. Prevalence and Genotype Distribution of Cervical High-Risk Human Papilloma Virus in Cervical Specimens of Woman with Normal and Abnormal Cytology in Anbar province, Iraq. International Journal of Drug Delivery Technology. 2021;11(1):1-6. ; DOI: 10.25258/ijddt.11.1.1
9. Katare KK, Mandapati U, Seelam M, Gundumolu SR, Vedula N. Development and Validation of RP-HPLC Method for the Simultaneous Determination of Cisplatin, Capecitabine and Trastuzumab. International Journal of Pharmaceutical Quality Assurance. 2022;13(1):30-38. DOI: 10.25258/ijpqa.13.1.8
10. Ke Z, Xu Y, Shu Y, Wang C, Wu B, Zhang B, Xiang P, Hu X. Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer. Translational Cancer Research. 2024; 13(2):676. https://doi.org/10.21037%2Ftcr-23-1680
11. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):475-480. DOI: 10.25258/ijpqa.14.3.03
12. Alubaidi GT. Virus-like Particles-Application in Nano Vaccines: A Review. International Journal of Drug Delivery Technology. 2020;10(3):366-368. DOI: 10.25258/ijddt.10.3.10
13. World Health Organization. Considerations for human papillomavirus (HPV) vaccine product choice. World Health Organization; 2024.